Aclaris Therapeutics Inc [ACRS] stock prices are up 3.11% to $1.99 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The ACRS shares have gain 10.56% over the last week, with a monthly amount glided 30.07%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Wedbush started tracking the stock with Outperform rating on May 28, 2025, and set its price target to $8. H.C. Wainwright upgraded its rating to a Buy but stick to its price target of $20 on December 23, 2024. Cantor Fitzgerald upgraded its rating to a Overweight. Leerink Partners upgraded its rating to Outperform for this stock on November 19, 2024, and upped its price target to $7. In a note dated November 19, 2024, Jefferies upgraded a Buy rating on this stock and boosted its target price from $2 to $7.
The stock price of Aclaris Therapeutics Inc [ACRS] has been fluctuating between $1.05 and $5.17 over the past year. Currently, Wall Street analysts expect the stock to reach $10.75 within the next 12 months. Aclaris Therapeutics Inc [NASDAQ: ACRS] shares were valued at $1.99 at the most recent close of the market. An investor can expect a potential return of 440.2% based on the average ACRS price forecast.
Analyzing the ACRS fundamentals
The Aclaris Therapeutics Inc [NASDAQ:ACRS] reported sales of 16.79M for trailing twelve months, representing a drop of -35.76%. Gross Profit Margin for this corporation currently stands at 0.24% with Operating Profit Margin at -8.73%, Pretax Profit Margin comes in at -8.02%, and Net Profit Margin reading is -8.02%. To continue investigating profitability, this company’s Return on Assets is posted at -0.71, Equity is -0.96 and Total Capital is -0.9. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.9200 points at the first support level, and at 1.8500 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.0700, and for the 2nd resistance point, it is at 2.1500.
Ratios To Look Out For
It’s worth pointing out that Aclaris Therapeutics Inc [NASDAQ:ACRS]’s Current Ratio is 3.88. On the other hand, the Quick Ratio is 3.88, and the Cash Ratio is 0.95. Considering the valuation of this stock, the price to sales ratio is 12.84, the price to book ratio is 1.64.
Transactions by insiders
Recent insider trading involved Mehra Anand, Director, that happened on Nov 19 ’24 when 0.67 million shares were purchased.
